Humacyte (NASDAQ:HUMA) Price Target Lowered to $1.25 at TD Cowen

Humacyte (NASDAQ:HUMA) had its price target dropped by research analysts at TD Cowen from $1.50 to $1.25 in a report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. TD Cowen’s target price would suggest a potential upside of 26.39% from the stock’s current price.

Several other brokerages have also issued reports on HUMA. Wall Street Zen upgraded Humacyte from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Humacyte in a research note on Friday, April 10th. BTIG Research reiterated a “buy” rating and issued a $2.00 price objective on shares of Humacyte in a report on Tuesday. D. Boral Capital reissued a “buy” rating and set a $25.00 price objective on shares of Humacyte in a research report on Tuesday, April 28th. Finally, HC Wainwright boosted their target price on shares of Humacyte from $3.00 to $4.00 and gave the company a “buy” rating in a report on Thursday, June 11th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $6.25.

Humacyte Trading Down 4.0%

Shares of NASDAQ HUMA traded down $0.04 during midday trading on Wednesday, hitting $0.99. 3,786,870 shares of the company traded hands, compared to its average volume of 6,746,621. Humacyte has a 12-month low of $0.55 and a 12-month high of $2.84. The firm has a market cap of $219.58 million, a P/E ratio of -1.74 and a beta of 2.45. The stock has a 50-day moving average price of $0.97 and a 200 day moving average price of $1.03. The company has a debt-to-equity ratio of 5.46, a quick ratio of 3.32 and a current ratio of 3.93.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. The company had revenue of $0.50 million during the quarter, compared to the consensus estimate of $1.46 million. Humacyte had a negative net margin of 4,836.06% and a negative return on equity of 2,914.18%. As a group, analysts expect that Humacyte will post -0.3 earnings per share for the current year.

Insider Transactions at Humacyte

In other news, CFO Dale A. Sander sold 45,887 shares of Humacyte stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $0.90, for a total value of $41,298.30. Following the completion of the transaction, the chief financial officer owned 267,213 shares of the company’s stock, valued at $240,491.70. The trade was a 14.66% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kathleen Sebelius purchased 56,818 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The stock was purchased at an average price of $0.88 per share, for a total transaction of $49,999.84. Following the purchase, the director owned 148,025 shares in the company, valued at $130,262. This represents a 62.30% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 3.10% of the company’s stock.

Institutional Trading of Humacyte

Institutional investors and hedge funds have recently bought and sold shares of the company. UBS Group AG grew its holdings in shares of Humacyte by 48.8% during the fourth quarter. UBS Group AG now owns 2,978,610 shares of the company’s stock valued at $2,862,000 after buying an additional 976,275 shares during the last quarter. Envestnet Asset Management Inc. purchased a new position in Humacyte in the 3rd quarter worth approximately $46,000. Cerity Partners LLC bought a new position in Humacyte in the 2nd quarter valued at approximately $35,000. Imprint Wealth LLC bought a new position in Humacyte in the 3rd quarter valued at approximately $33,000. Finally, Equitable Holdings Inc. purchased a new stake in Humacyte during the 3rd quarter valued at $29,000. 44.71% of the stock is currently owned by institutional investors.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.